Literature DB >> 14502004

Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection.

Christoph G Lange1, Michael M Lederman, Kathy Medvik, Robert Asaad, Mary Wild, Robert Kalayjian, Hernan Valdez.   

Abstract

OBJECTIVE: To ascertain whether delaying the initiation of highly active antiretroviral therapy (HAART) compromises functional immune reconstitution in HIV-1 infection in persons who regain 'normal' CD4 T-cell counts after suppressive antiretroviral therapies.
DESIGN: Prospective open-label study carried out at two University-affiliated HIV-outpatient clinics in the USA. SUBJECTS AND METHODS: Response to immunization was used as a model for in vivo functional immune competence in 29 HIV-1 infected patients with CD4 T-cell counts > 450 x 106 cells/l and HIV-RNA < 400 copies/ml for > 12 months after HAART and nine HIV-1 seronegative controls. After immunization with tetanus toxoid, diphtheria-toxoid, and keyhole limpet hemocyanin, immune response scores (IRS) were calculated using postimmunization antibody concentrations, lymphocyte proliferation, and delayed-type hypersensitivity responses to vaccine antigens.
RESULTS: Despite normal numbers of circulating CD4 T-cells, the CD4 T-cell nadir before HAART initiation predicted the immune response to immunization (rho = 0.5; P < 0.005) while current CD4 T-cell count did not. Likewise, CD4 T-lymphocyte expression of the co-stimulatory molecule CD28 was also an independent predictor of response to immunization (rho = 0.5; P < 0.005).
CONCLUSIONS: Even among persons who controlled HIV replication and normalized CD4 T-cell counts with HAART, pretreatment CD4 T-cell count and numbers of circulating CD4+CD28+ T-cells at immunization, but not current CD4 T-cell count, predict the ability to respond to vaccination. Delaying the initiation of HAART in chronic HIV-1 infection results in impaired functional immune restoration despite normalization of circulating CD4 T-cell numbers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14502004     DOI: 10.1097/00002030-200309260-00002

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  63 in total

1.  Dissociation of CD154 and cytokine expression patterns in CD38+ CD4+ memory T cells in chronic HIV-1 infection.

Authors:  Enrique Espinosa; Christopher E Ormsby; Gustavo Reyes-Terán; Robert Asaad; Scott F Sieg; Michael M Lederman
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

2.  Highly active antiretroviral therapy in patients infected with human immunodeficiency virus increases CD40 ligand expression and IL-12 production in cells ex vivo.

Authors:  Alice M Nyakeriga; Jun Ying; Norah J Shire; Carl J Fichtenbaum; Claire A Chougnet
Journal:  Viral Immunol       Date:  2011-08       Impact factor: 2.257

Review 3.  Antiretroviral treatment of HIV infected adults.

Authors:  Steven G Deeks
Journal:  BMJ       Date:  2006-06-24

Review 4.  When to start antiretroviral therapy.

Authors:  Cunlin Wang; Saba W Masho; Daniel E Nixon
Journal:  Curr HIV/AIDS Rep       Date:  2006-07       Impact factor: 5.071

5.  Functional impairment of CD4 T cells despite normalization of T cell number in HIV.

Authors:  Kenneth S Knox; Richard B Day; Lisa M Kohli; Chadi A Hage; Homer L Twigg
Journal:  Cell Immunol       Date:  2006-10-30       Impact factor: 4.868

Review 6.  HIV infection, inflammation, immunosenescence, and aging.

Authors:  Steven G Deeks
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

Review 7.  Study design issues in evaluating immune biomarkers.

Authors:  Ronald J Bosch; Xinyan Zhang; Netanya G Sandler
Journal:  Curr Opin HIV AIDS       Date:  2013-03       Impact factor: 4.283

8.  A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy.

Authors:  Jeffrey M Jacobson; Hongying Wang; Rebeka Bordi; Lu Zheng; Barry H Gross; Alan L Landay; John Spritzler; Jean-Pierre Routy; Constance Benson; Judith Aberg; Pablo Tebas; David W Haas; Jennifer Tiu; Kristine Coughlin; Lynette Purdue; Rafick-Pierre Sekaly
Journal:  J Acquir Immune Defic Syndr       Date:  2014-08-01       Impact factor: 3.731

9.  Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection.

Authors:  Eleanor M P Wilson; Amrit Singh; Katherine Huppler Hullsiek; Dave Gibson; W Keith Henry; Ken Lichtenstein; Nur F Önen; Erna Kojic; Pragna Patel; John T Brooks; Irini Sereti; Jason V Baker
Journal:  J Infect Dis       Date:  2014-05-09       Impact factor: 5.226

10.  Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm³.

Authors:  Constanza Lucero; Berta Torres; Agathe León; Marta Calvo; Lorna Leal; Iñaki Pérez; Montserrat Plana; Mireia Arnedo; Josep Mallolas; Josep M Gatell; Felipe García
Journal:  AIDS Res Hum Retroviruses       Date:  2013-04-18       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.